SmartMed Technologies’ scientists researched that pancreatic neuroendocrine cancer begins in cells that produce hormones such as insulin and then it spreads by attacking the immune system’s response to viral infections.

SmartMed Technologies’ Chief Medical Officer, Dr. Norman Hammond commented on the research of pancreatic cancer saying “Our study found that these type of tumors can evade immune attack by hijacking the immune system’s response to viral infections. In most cases, only one in four people will survive for more than five years, which means the need for more and new treatment options, and this is where immunotherapy which target certain cells can possibly treat this rare form of pancreatic cancer.”

“What we found is that there is a complex interplay between cancer and immune cells in the most aggressive type of pancreatic neuroendocrine tumors, which we strongly believe that immunotherapy could work for patients with this rare form of the disease. We are extremely optimistic that we can translate our technology into clinical trials to test the benefit of different immunotherapies to combat pancreatic cancer,” added Dr. Norman Hammond, Chief Medical Officer of SmartMed Technologies.

About Us - SmartMed Technologies

SmartMed Technologies is a pioneering bioinformatics medical research and development company focused on delivering innovative medical products through artificial intelligence technology to combat prevalent, rare and emerging diseases.

Based in Seoul, our team collects and analyzes big data, utilizing artificial intelligence to gain insight into complex diseases such as leukemia and different cancers. Our approach centers on genome integration with high-performance computers and deep artificial intelligence learning.

With our advanced technology, we have been able to cut costs arising from industry trial-and-error procedures; with the integration of supercomputers into our work, we are able to run more comprehensive simulations, better target proteins, discover new drug compounds for a multitude of diseases, and generally increase our capacity for successful drug development.

With international recognition for our research and projects, some in collaboration with world-renowned institutions, we consistently aim to develop our understanding in the medical field through artificial intelligence and advanced clinical trials.